Some AMD Patients May Not Respond to Intravitreal Aflibercept

Source: Reuters

Although intravitreal aflibercept is effective in the great majority of treatment-naive cases of neovascular age-related macular degeneration (AMD), the drug may not work for a small subgroup of patients with choroidal vascular hyperpermeability, Japanese researchers say, according to a report in Medscape.

In a retrospective case series, online June 15 in the British Journal of Ophthalmology, they found primary failure of intravitreal aflibercept occurred in only 5.2% of patients. By contrast, non-response rates between 10.1% and 45% have been reported with intravitreal ranibizumab.

“Although aflibercept has been considered more effective than bevacizumab or ranibizumab based on its higher affinity to VEGF-A (vascular endothelial growth factor A) and a longer half-life, the efficacy of aflibercept is still not sufficient to completely resolve the exudation in some patients with choroidal vascular hyperpermeability,” write Dr. Chikako Hara and colleagues of Osaka University Graduate School of Medicine in Suita.

Read the full article.

Related Content